HIF in Nephrotoxicity During Cisplatin Chemotherapy: Regulation, Function and Therapeutic Potential

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jan 12

PMID 33430279

Citations 4

Authors

Siyao Li

Lu Wen

Xiaoru Hu

Qingqing Wei

Zheng Dong

Affiliations

Soon will be listed here.

Abstract

Cisplatin is a highly effective, broad-spectrum chemotherapeutic drug, yet its clinical use and efficacy are limited by its side effects. Particularly, cancer patients receiving cisplatin chemotherapy have high incidence of kidney problems. Hypoxia-inducible factor (HIF) is the "master" transcription factor that is induced under hypoxia to trans-activate various genes for adaptation to the low oxygen condition. Numerous studies have reported that HIF activation protects against AKI and promotes kidney recovery in experimental models of cisplatin-induced acute kidney injury (AKI). In contrast, little is known about the effects of HIF on chronic kidney problems following cisplatin chemotherapy. Prolyl hydroxylase (PHD) inhibitors are potent HIF inducers that recently entered clinical use. By inducing HIF, PHD inhibitors may protect kidneys during cisplatin chemotherapy. However, HIF activation by PHD inhibitors may reduce the anti-cancer effect of cisplatin in tumors. Future studies should test PHD inhibitors in tumor-bearing animal models to verify their effects in kidneys and tumors.

Citing Articles

Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy.

Song C, Kim H, Kim M, Park H, Paek S, Terezakis S Cancer Res Treat. 2024; 57(1):1-10.

PMID: 38853541 PMC: 11729307. DOI: 10.4143/crt.2024.255.

Computational Gene Expression and Network Analysis of Myc Reveal Insights into Its Diagnostic and Prognostic Role in Subtypes of Renal Cancer.

Priyam J, Saxena U Appl Biochem Biotechnol. 2023; 195(7):4251-4276.

PMID: 36689165 DOI: 10.1007/s12010-023-04357-5.

Novel Compounds as PHD Inhibitors for Treating Heart, Lung, Liver, and Kidney Diseases.

Sabnis R ACS Med Chem Lett. 2021; 12(12):1868-1869.

PMID: 34917238 PMC: 8667062. DOI: 10.1021/acsmedchemlett.1c00570.

Glucose Metabolism in Acute Kidney Injury and Kidney Repair.

Wen L, Li Y, Li S, Hu X, Wei Q, Dong Z Front Med (Lausanne). 2021; 8:744122.

PMID: 34912819 PMC: 8666949. DOI: 10.3389/fmed.2021.744122.

HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review.

Hirota K Biomedicines. 2021; 9(5).

PMID: 33923349 PMC: 8146675. DOI: 10.3390/biomedicines9050468.

References

Cadenas S . ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic Biol Med. 2018; 117:76-89. DOI: 10.1016/j.freeradbiomed.2018.01.024. View

Yang C, Guo Y, Huang T, Zhao J, Huang X, Tang H . Asiatic acid protects against cisplatin-induced acute kidney injury via anti-apoptosis and anti-inflammation. Biomed Pharmacother. 2018; 107:1354-1362. DOI: 10.1016/j.biopha.2018.08.126. View

Sun R, Meng X, Pu Y, Sun F, Man Z, Zhang J . Overexpression of HIF-1a could partially protect K562 cells from 1,4-benzoquinone induced toxicity by inhibiting ROS, apoptosis and enhancing glycolysis. Toxicol In Vitro. 2018; 55:18-23. DOI: 10.1016/j.tiv.2018.11.005. View

Semenza G . Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med. 2010; 2(3):336-361. DOI: 10.1002/wsbm.69. View

Landau S, Guo X, Velazquez H, Torres R, Olson E, Garcia-Milian R . Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney Int. 2019; 95(4):797-814. PMC: 6543531. DOI: 10.1016/j.kint.2018.11.042. View

Kapitsinou P, Jaffe J, Michael M, Swan C, Duffy K, Erickson-Miller C . Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. Am J Physiol Renal Physiol. 2012; 302(9):F1172-9. PMC: 3362175. DOI: 10.1152/ajprenal.00667.2011. View

Maxwell P, Eckardt K . HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2015; 12(3):157-68. DOI: 10.1038/nrneph.2015.193. View

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

10.

Koh M, Powis G . Passing the baton: the HIF switch. Trends Biochem Sci. 2012; 37(9):364-72. PMC: 3433036. DOI: 10.1016/j.tibs.2012.06.004. View

11.

Wu Y, Jiang Z, Li Z, Gu J, You Q, Zhang X . Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. J Med Chem. 2018; 61(12):5332-5349. DOI: 10.1021/acs.jmedchem.8b00549. View

12.

Kong T, Eltzschig H, Karhausen J, Colgan S, Shelley C . Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc Natl Acad Sci U S A. 2004; 101(28):10440-5. PMC: 478589. DOI: 10.1073/pnas.0401339101. View

13.

Sharp C, Doll M, Megyesi J, Oropilla G, Beverly L, Siskind L . Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. Am J Physiol Renal Physiol. 2018; 315(1):F161-F172. PMC: 6087791. DOI: 10.1152/ajprenal.00636.2017. View

14.

Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V . Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res. 2003; 63(24):8777-83. View

15.

Mokas S, Lariviere R, Lamalice L, Gobeil S, Cornfield D, Agharazii M . Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. Kidney Int. 2016; 90(3):598-609. DOI: 10.1016/j.kint.2016.05.020. View

16.

Jain S, Maltepe E, Lu M, Simon C, Bradfield C . Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech Dev. 1998; 73(1):117-23. DOI: 10.1016/s0925-4773(98)00038-0. View

17.

Lisy K, Peet D . Turn me on: regulating HIF transcriptional activity. Cell Death Differ. 2008; 15(4):642-9. DOI: 10.1038/sj.cdd.4402315. View

18.

Keremu A, Aini A, Maimaitirexiati Y, Liang Z, Aila P, Xierela P . Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α. Biosci Rep. 2017; 39(11). PMC: 6859113. DOI: 10.1042/BSR20170080. View

19.

Hussain I, Waheed S, Ahmad K, Pirog J, Syed V . Scutellaria baicalensis targets the hypoxia-inducible factor-1α and enhances cisplatin efficacy in ovarian cancer. J Cell Biochem. 2018; 119(9):7515-7524. DOI: 10.1002/jcb.27063. View

20.

Koh M, Powis G . HAF : the new player in oxygen-independent HIF-1alpha degradation. Cell Cycle. 2009; 8(9):1359-66. PMC: 2700049. DOI: 10.4161/cc.8.9.8303. View